Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa
- PMID: 24127451
- DOI: 10.1200/JCO.2013.51.0289
Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa
Comment in
-
Reply to F. Ades.J Clin Oncol. 2013 Nov 20;31(33):4272. doi: 10.1200/JCO.2013.52.4520. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127453 No abstract available.
Comment on
-
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509322 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
